On November 16, 2020 PharmAbcine Inc. (KOSDAQ: 208340ks) reported that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020 (Press release, PharmAbcine, NOV 16, 2020, View Source [SID1234571180]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical study was conducted in Australia from 2016- 2017. In the study, 25% of the patients had stable disease and 40% of the patients had relief from brain edema. The data from the study suggested the possibility of using Olinvacimab for rGBM patients who no longer respond to Avastin in treating severe brain edema.

In 2017, PharmAbcine received approval from the US FDA (Food and Drug Administration) for the Phase II clinical study of Olinvacimab for Avastin-refractory rGBM patients. Furthermore, Olinvacimab received Orphan Drug Designation (ODD) from both the US FDA and the Korean MFSD (Ministry of Food and Drug Safety) in 2018. Beginning in 2019, the Phase II clinical trial is currently on-going.

Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor with a fast growth rate. Recurrent glioblastoma multiforme (rGBM) is a disease in which the GBM recur after surgery and drug/radiation therapy. It is known that rGBM has an average life expectancy of about 4 months and causes extensive brain edema.

About Society of Neuro-Oncology Annual Meeting

Society of Neuro-Oncology Annual Meeting is the world’s largest neuro-oncology society held every year. This year marks 25th event with more than 2600 researchers and experts participating from more than 40 countries around the world. Through this event, many global pharmaceutical companies will present various cutting-edge technologies and advance their academic and research efforts in the field of neuro-oncology. SNO 2020 will be held virtually from November 19 to 21.